Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
328 stopped studies mapped to Myelodysplastic Syndrome and descendants · 88% state a reason
Over the 328 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03494569 | Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell… | Phase 1 | suspended | Apr 11, 2018 | City of Hope Medical Center | Accrual goal | Enrollment / accrual |
| NCT04021368 | RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome | Phase 1 | terminated | Jul 16, 2019 | Ryvu Therapeutics SA | RPD2 has been identified | Other (stated, no rule matched) |
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | Phase 2 | suspended | Nov 8, 2024 | Leland Metheny | insufficient funding | Funding |
| NCT06704152 | BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant… | Phase 1 / Phase 2 | terminated | Nov 25, 2024 | BlueSphere Bio, Inc | Company Decision | Sponsor / business decision |
| NCT06888323 | Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients… | Phase 1 | suspended | Mar 21, 2025 | National Cancer Institute (NCI) | Drug Supply Issues | Drug supply |
| NCT02392572 | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | M.D. Anderson Cancer Center | \<75% participants | Other (stated, no rule matched) |
| NCT07387354 | Pacritinib With Aza for Upfront Myelodysplastic Syndrome(MDS) | Phase 1 / Phase 2 | withdrawn | Feb 4, 2026 | Thomas Jefferson University | FDA requested significant changes to the study protocol | Other (stated, no rule matched) |
| NCT06492707 | DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse… | Phase 1 | suspended | Jul 9, 2024 | Fred Hutchinson Cancer Center | Recruitment on hold with plans to open to accrual again soon. | Enrollment / accrual |
| NCT04994808 | Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem… | Phase 2 | terminated | Aug 6, 2021 | Fred Hutchinson Cancer Center | The study was closed due to the end of funding. | Funding |
| NCT06021600 | A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to… | Phase 1 | terminated | Sep 1, 2023 | M.D. Anderson Cancer Center | Slow participant enrollment | Enrollment / accrual |
| NCT03969446 | Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute… | Phase 1 | suspended | May 31, 2019 | City of Hope Medical Center | Accrual goal Met | Enrollment / accrual |
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming… | Phase 1 | suspended | Jun 1, 2022 | David Wald | Drugs unavailable | Other (stated, no rule matched) |
| NCT05086315 | First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult… | Phase 1 / Phase 2 | terminated | Oct 20, 2021 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT03146871 | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or… | Phase 2 | terminated | May 10, 2017 | University of Southern California | Lack of funding | Funding |
| NCT04550442 | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk… | Phase 1 / Phase 2 | terminated | Sep 16, 2020 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06630221 | Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations | Phase 2 | suspended | Oct 8, 2024 | Abhay Singh, MD MPH | Funding unavailable | Funding |
| NCT04250051 | Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or… | Phase 1 | terminated | Jan 31, 2020 | Northwestern University | Low accrual | Enrollment / accrual |
| NCT01135329 | Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose… | Phase 2 | terminated | Jun 2, 2010 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The stopping rule was met and hence the study was closed | Other (stated, no rule matched) |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for… | N/A | terminated | Oct 14, 2013 | Masonic Cancer Center, University of Minnesota | No longer a research question to answer. | Other (stated, no rule matched) |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity… | Phase 2 | terminated | Aug 11, 2017 | Fred Hutchinson Cancer Center | Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and… | Safety / toxicity |
| NCT04639024 | ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN | Phase 2 | terminated | Nov 20, 2020 | Gwynn Long, M.D. | ADCT is reallocating all resources to the phase III program. | Other (stated, no rule matched) |
| NCT05607199 | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and…(BHARAT-1) | Phase 1 | terminated | Nov 7, 2022 | Aurigene Discovery Technologies Limited | Patient recruitment problems. | Enrollment / accrual |
| NCT05263271 | Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome | Phase 1 | terminated | Mar 2, 2022 | Changchun GeneScience Pharmaceutical Co., Ltd. | Adjusted the product development strategy. | Sponsor / business decision |
| NCT01366612 | Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation(FLUBUTBI) | Phase 3 | terminated | Jun 6, 2011 | Hackensack Meridian Health | Lack of Accrual | Enrollment / accrual |
| NCT02333162 | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in… | Phase 1 | suspended | Jan 7, 2015 | University of Chicago | Enrollment on hold pending amendment | Enrollment / accrual |
| NCT03150004 | Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With… | Phase 2 | terminated | May 11, 2017 | Medical College of Wisconsin | No longer have funding support to complete the pharmacogenetics component. | Funding |
| NCT05933070 | A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or…(LAUREL) | Phase 1 | terminated | Jul 6, 2023 | Inmune Bio, Inc. | Slow/low Enrollment | Enrollment / accrual |
| NCT04278768 | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute… | Phase 1 / Phase 2 | suspended | Feb 20, 2020 | Curis, Inc. | Dosing completed in all cohorts. Planning underway for potential additional patient cohorts. | Other (stated, no rule matched) |
| NCT05275439 | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | Phase 1 | terminated | Mar 11, 2022 | Shattuck Labs, Inc. | Development discontinued | Other (stated, no rule matched) |
| NCT04953312 | Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)(CALPRO) | N/A | withdrawn | Jul 7, 2021 | Assistance Publique - Hôpitaux de Paris | Abandonment of the study project | Other (stated, no rule matched) |
| NCT03404193 | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid… | Phase 2 | terminated | Jan 19, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03772925 | Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute… | Phase 1 | terminated | Dec 12, 2018 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT05170828 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | Phase 1 | withdrawn | Dec 28, 2021 | Ossium Health, Inc. | Change in Study Design | Other (stated, no rule matched) |
| NCT04328714 | Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host… | Phase 1 | terminated | Mar 31, 2020 | Edwin Horwitz | Study was suspended pending renovation and reopening of the facility manufacturing the study… | Drug supply |
| NCT06284460 | Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029,… | Phase 1 / Phase 2 | withdrawn | Feb 29, 2024 | M.D. Anderson Cancer Center | Drug Source Request | Other (stated, no rule matched) |
| NCT04160052 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory… | Phase 1 / Phase 2 | terminated | Nov 12, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT02381548 | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Mar 6, 2015 | National Cancer Institute (NCI) | Other - Adverse Events | Safety / toxicity |
| NCT04266301 | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With…(STIMULUS-MDS2) | Phase 3 | terminated | Feb 12, 2020 | Novartis Pharmaceuticals | In December 2023, Novartis decided to terminate the sabatolimab clinical development program early… | Safety / toxicity |
| NCT05918055 | Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic… | Phase 1 / Phase 2 | terminated | Jun 26, 2023 | National Cancer Institute (NCI) | Drug company withdrew support. | Sponsor / business decision |
| NCT06454409 | Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients… | Phase 1 | suspended | Jun 12, 2024 | City of Hope Medical Center | resources | Other (stated, no rule matched) |
| NCT04937166 | A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological… | Phase 1 | terminated | Jun 23, 2021 | Kahr Medical | Slow enrolment | Enrollment / accrual |
| NCT04874194 | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid… | Phase 1 / Phase 2 | terminated | May 5, 2021 | M.D. Anderson Cancer Center | The study terminated early because the company was longer providing the investigational product. | Sponsor / business decision |
| NCT04582539 | To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic…(LIMBER) | Phase 1 / Phase 2 | terminated | Oct 9, 2020 | Incyte Corporation | Strategic Business Decision | Sponsor / business decision |
| NCT03940352 | HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia… | Phase 1 | terminated | May 7, 2019 | Novartis Pharmaceuticals | Business decision | Sponsor / business decision |
| NCT05148234 | BMS-986253 in Myelodysplastic Syndromes | Phase 1 / Phase 2 | terminated | Dec 8, 2021 | National Cancer Institute (NCI) | Company closed the trial. | Sponsor / business decision |
| NCT05358808 | ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded…(ACHIEVE) | Phase 2 | terminated | May 3, 2022 | TC Biopharm | The Trial was early terminated due to deficiencies in the Achieve Protocol: V8.0 dated 19 January… | Other (stated, no rule matched) |
| NCT05168202 | A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and… | Phase 1 | terminated | Dec 23, 2021 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT04951778 | Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With… | Phase 1 | terminated | Jul 7, 2021 | Celgene | Efficacy endpoint met; however, overall experimental dosing regimen is not considered optimal to… | Efficacy / futility |
| NCT04849910 | Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein,… | Phase 1 / Phase 2 | terminated | Apr 19, 2021 | Vor Biopharma | Lack of Funding | Funding |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 hours agoSource updated Sep 28, 2026source: clinicaltrials